Home | Site Map | Contact Us | Bookmark  
 
  Single Disease Educational Content
  Multi-Disease
Educational Content
  Other Resources
  About CLDF
 
 

Hepatitis B Virus (HBV)

  Additional content on this specific disease state can be found in the:     Click on another disease specific
area listed above to view content
 

Liver News Library
 
 
 
 
 
Goal Statement
The goal of this program is to provide important clinical data on the management of HBV.
 
Target Audience
This activity has been designed to meet the educational needs of healthcare practitioners involved in the care of patients with HBV
 
 

 View Webcasts
 
 
Jointly sponsored by Purdue University School of Pharmacy
and the Chronic Liver Disease Foundation.

Supported by an independent educational grant
from Gilead Sciences Medical Affairs.
 
 
 
 
Target Audience
This activity has been designed to meet the educational needs of gastroenterologists, physician assistants, and nurse practitioners involved in the care of patients with HBV.
 
Goal Statement
The goal of this program is to provide important clinical data on the management of hepatitis B.
 
Educational Objectives
After completing this activity, the participants should be better able to:
Understand the natural history and management of HBV
Describe algorithms and guidelines for treatment
Compare and contrast currently available treatment modalities
Highlight the latest clinical research in HBV
 
Dinner Meeting & Teleweb Series     

 View Locations, Dates & Register
 

 Download Brochure Request Form
 
Jointly sponsored by Purdue University School of Pharmacy and the Chronic Liver Disease Foundation
This activity supported by: Bristol-Myers Squibb.
 
 
       

  

Hepatology 2009 Current Perspectives on Chronic Liver Disease   (Recorded East Coast Satellite Broadcast Webcast)
      No CME credit available

  

Natural History and Clinical Course of Chronic   (Symposium Webcast)
  Hepatitis B
Presented by: Steven Han, MD
  No CME credit available

  

Optimizing Outcomes: Clinical Decisions in HBV   (Symposium Webcast)
  Resistance and Long Term Therapy   No CME credit available

  

Management of HBV HBeAg Positive Patients -   (2 Webcasts)
  Presented by: Dr.Tram Tran & Dr. Mack Mitchell   No CME credit available

  

Management of HBV HBeAg Negative Patients -   (2 Webcasts)
  Presented by: Dr. Naoky Tsai & Dr. Eddie Cheung   No CME credit available

  

Current Guidelines in the Management of HBV   (Webcast)
  Patients   No CME credit available

  

Managing Treatment Resistance in HBV Patients   (Webcast)
      No CME credit available
 
 
 
  1. Celiac Disease as a Cause of Abnormal Transaminases in Chronic Hepatitis B Infection
    Clark LE, Herrera JL. PRACTICAL GASTROENTEROLOGY • DECEMBER 2003;27:50-51.

  2. Chronic Hepatitis B: Who and How to Treat
    Landreneau SW, Herrera JL. PRACTICAL GASTROENTEROLOGY • NOVEMBER 2007;31:25-40.

  3. Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis B
    Jung YK, Yeon JE, Han WS, Kim JH, Kim JH, Park JJ, Kim JS, Bak YT, Yoo W, Hong SP, Kim SO, Kwon SY, Byun KS, Lee CH. Gut Liver. 2010 Jun;4(2):212-8. Epub 2010 Jun 16.

  4. Correlation between clinical indication for treatment and liver histology in HBeAg-negative chronic hepatitis B: a novel role of alpha-fetoprotein
    Lee IC, Huang YH, Chan CC, Huo TI, Chu CJ, Lai CR, Lee PC, Su CW, Hung HH, Wu JC, Lin HC, Lee SD. Liver Int. 2010 Jun 15. [Epub ahead of print]

  5. Cost-Effectiveness of Nucleoside Analog Therapy for Hepatitis B in China: A Markov Analysis
    Wu B, Li T, Chen H, Shen J. Value Health. 2010 Apr 30. [Epub ahead of print]

  6. Does chemotherapy prevent HBV-related hepatocellular carcinoma? Cons
    Colombo M. Dig Liver Dis. 2010 Jul;42 Suppl 3:S298-301.

  7. On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective
    Chien RN. J Gastroenterol Hepatol. 2010 May;25(5):852-7.

  8. Overlap/switch to adefovir monotherapy for lamivudine-resistant patients who responded to combination therapy: a pilot controlled study
    Aizawa M, Tsubota A, Fujise K, Sato K, Baba M, Takamatsu M, Namiki Y, Ohkusa T, Tajiri H. Intern Med. 2010;49(12):1067-72. Epub 2010 Jun 15.

  9. PNA Array for Detection of Point Mutations in Hepatitis B Virus Associated with Antiviral Resistance
    Jang H, Kim J, Choi JJ, Son Y, Park H. J Clin Microbiol. 2010 Jun 23. [Epub ahead of print]

  10. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis
    Shi Z, Yang Y, Ma L, Li X, Schreiber A. Obstet Gynecol. 2010 Jul;116(1):147-59.

  11. Long-Term Outcome of Renal Transplant Recipients With Chronic Hepatitis B Infection-Impact of Antiviral Treatments
    Yap DY, Tang CS, Yung S, Choy BY, Yuen MF, Chan TM. Transplantation. 2010 Jun 17. [Epub ahead of print]

  12. Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients
    Suzuki F, Akuta N, Suzuki Y, Yatsuji H, Sezaki H, Arase Y, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Watahiki S, Kumada H. J Gastroenterol Hepatol. 2010 May;25(5):892-8.

  13. Chronic Viral Infections and Invasive Procedures: Risk of Vertical Transmission and Current Recommendations
    López M, Coll O. Fetal Diagn Ther. 2010 Jun 19. [Epub ahead of print]

  14. Cryoglobulinemic glomerulonephritis in chronic hepatitis B infection
    Enríquez R, Sirvent AE, Andrada E, Escolano C, Rodríguez JC, Millán I, Gutiérrez F, Amorós F. Ren Fail. 2010 May;32(4):518-22.

  15. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection
    Yokosuka O, Takaguchi K, Fujioka S, Shindo M, Chayama K, Kobashi H, Hayashi N, Sato C, Kiyosawa K, Tanikawa K, Ishikawa H, Masaki N, Seriu T, Omata M. J Hepatol. 2010 Mar 24. [Epub ahead of print]

  16. Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance: A Community-based Follow-up Study
    Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, You SL, Iloeje UH, Chen CJ; R.E.V.E.A.L.-HBV Study Group. Gastroenterology. 2010 Apr 28. [Epub ahead of print]

  17. High Hepatitis B Viral Load Predicts Recurrence of Small Hepatocellular Carcinoma after Curative Resection
    Qu LS, Jin F, Huang XW, Shen XZ. J Gastrointest Surg. 2010 Apr 27. [Epub ahead of print]

  18. Liver transplant from Anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it safe? A systematic review of the literature.
    Avelino-Silva VI, D Albuquerque LA, Bonazzi PR, Song AT, Miraglia JL, de Brito Neves A, Abdala E. Clin Transplant. 2010 Apr 28. [Epub ahead of print]

  19. Hepatitis B virus infection and liver transplantation
    Kennedy M, Alexopoulos SP. Curr Opin Organ Transplant. 2010 May 4. [Epub ahead of print]

  20. Noninvasive markers to diagnose cirrhosis in patients with HBeAg positive chronic hepatitis: Do new biomarkers improve the accuracy?
    Park SH, Kim DJ, Cheong JY, Cho SW, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB. Clin Biochem. 2010 Apr 27. [Epub ahead of print]

  21. Prevention of hepatitis B virus reactivation in B-cell lymphoma patients receiving chemotherapy with rituximab
    Mimura N, Kojima H, Tsujimura H, Ise M, Sakai C, Fukai K, Yokosuka O, Kumagai K. Rinsho Ketsueki. 2010 Mar;51(3):213-5.

  22. Viral resistance in hepatitis B: prevalence and management
    Poordad F, Chee GM. Curr Gastroenterol Rep. 2010 Feb;12(1):62-9.

  23. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients
    Zheng MH, Shi KQ, Dai ZJ, Ye C, Chen YP. Clin Ther. 2010 Apr;32(4):649-58.

  24. Drug Delivery Systems and Liver Targeting for the Improved Pharmacotherapy of the Hepatitis B Virus (HBV) Infection
    Cuestas ML, Mathet VL, Oubiña JR, Sosnik A. Pharm Res. 2010 Mar 24. [Epub ahead of print]

  25. Multiple Clusters of Hepatitis Virus Infections Associated with Anesthesia for Outpatient Endoscopy Procedures
    Gutelius B, Perz JF, Parker MM, Hallack R, Stricof R, Clement EJ, Lin Y, Xia GL, Punsalang A, Eramo A, Layton M, Balter S. Gastroenterology. 2010 Mar 27. [Epub ahead of print]

  26. Hepatitis B Virus DNA in Saliva from children with Chronic Hepatitis B Infection: Implications for Saliva as a potential mode of horizontal transmission
    Heiberg IL, Hoegh M, Ladelund S, Niesters HG, Hogh B. Pediatr Infect Dis J. 2010 Mar 23. [Epub ahead of print]

  27. HBV replication is significantly reduced by IL-6
    Kuo TM, Hu CP, Chen YL, Hong MH, Jeng KS, Liang CC, Chen ML, Chang C. J Biomed Sci. 2009 Apr 20;16:41.

  28. Prevalence and impact of occult hepatitis B infection in chronic hepatitis C patients treated with pegylated interferon and ribavirin
    Levast M, Larrat S, Thelu MA, Nicod S, Plages A, Cheveau A, Zarski JP, Seigneurin JM, Morand P, Leroy V. J Med Virol. 2010 Mar 24;82(5):747-754. [Epub ahead of print]

  29. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review
    Saab S, Waterman B, Chi AC, Tong MJ. Liver Transpl. 2010 Mar;16(3):300-7.

  30. Chronic hepatitis B infection and risk of atherosclerosis-related mortality: A 17-year follow-up study based on 22,472 residents in Taiwan
    Wang CH, Chen CJ, Lee MH, Yang HI, Hsiao CK. Atherosclerosis. 2010 Mar 10. [Epub ahead of print]

  31. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: Prevalence, racial/ethnic differences, and viral interactions
    Bini EJ, Perumalswami PV. Hepatology. 2009 Nov 30. [Epub ahead of print]

  32. Toward elimination and eradication of hepatitis B
    Chen DS. J Gastroenterol Hepatol. 2010 Jan;25(1):19-25

  33. Hepatitis B and hepatocellular carcinoma
    Di Bisceglie A. Hepatology 2009;49(S6):S56-60)

  34. Identification of Acute Self-limited Hepatitis B among Patients Presenting with Hepatitis B Virus-related Acute Hepatitis: a Hospital-based
    Han YN. J Int Med Res. 2009 Nov-Dec;37(6):1952-60

  35. What Made a Successful Hepatitis B Program for Reducing Liver Cancer Disparities: An Examination of Baseline Characteristics and Educational Intervention, Infection Status, and Missing Responses of At-Risk Asian Americans
    Hsu CE, Zhang G, Yan FA, Shang N, Le T. J Community Health. 2010 Feb 5. [Epub ahead of print]

  36. Hepatitis B and Hepatitis C Prevalence and Treatment Referral Among Asian Americans Undergoing Community-Based Hepatitis Screening
    Hwang JP, Mohseni M, Gor BJ, Wen S, Guerrero H, Vierling JM. Am J Public Health 2010[Epub ahead of print]

  37. Epdemiology of hepatitis B in the United States
    Kim RW. Hepatology 2009;49:S28-S34

  38. The natural history of chronic hepatitis B virus infection
    McMahon B. Hepatology 2009;49(S6):S46-S55

  39. Effect of Needle Length When Immunizing Obese Adolescents With Hepatitis B Vaccine
    Middleman AB, Anding R, Tung C. Pediatrics. 2010 Feb 8. [Epub ahead of print]

  40. NIH Consensus Development Conference Statement on Management of Hepatitis B
    October 20-22, 2008

  41. Is response to antiviral treatment influenced by hepatitis B virus genotype?
    Raimondi S, Maisonneuve P, Bruno S, Mondelli MU. J Hepatol. 2010 Jan 6. [Epub ahead of print]

  42. Evaluation of the patient with hepatitis B
    Rotman Y, Brown T, Hoofnagle J. Hepatology 2009;49(S6):S22-S27

  43. End points of therapy in chronic hepatitis B
    Si Ahmed SN, Ecochard M, Zoulim F. Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):37-49

  44. Eliminating the Blood: Ongoing Outbreaks of Hepatitis B Virus Infection and the Need for Innovative Glucose Monitoring Technologies
    Thompson ND, Perz JF. J Diabetes Sci Technol. 2009 Mar 1;3(2):283-288

  45. Treatment of hepatitis B virus-associated glomerulonephritis: A meta-analysis
    Zhang Y, Zhou JH, Yin XL, Wang FY. World J Gastroenterol. 2010 Feb 14;16(6):770-7

  46. Evaluation of the patient with hepatitis B
    Rotman Y, Brown TA, Hoofnagle JH. Hepatology 2009;49(S5):S22-S27

  47. Special populations with hepatitis B virus infection
    Peters MG. Hepatology 2009;49(S5):S146-S155

  48. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochrondrial toxicity
    Tateo M, Roque-Afonso AM, Antonini TM, Medja F, Lombes A, Jardel C, Teicher E, Sebagh M, Roche B, Castaing D, Samuel D, Duclos-Vallee JC.AIDS. 2009 May 4 (Epub ahead of print)

  49. Prevalence and Factors Related to Hepatitis B and C in Inflammatory Bowel Disease Patients in Spain: A Nationwide, Multicenter Study
    Loras C, Saro C, Gonzalez-Huix F, et al. Am J Gastroenterol 2009;104:57-63.

  50. Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
    Marcellin P, Heathcote E, Buti M, et al. N Engl Med 2008;359:2442-2455.

  51. Hepatitis B: Reflections on the current approach to antiviral therapy
    Zoulim F, Perrillo R. J Hepatol 2008;48:S2-S19.

  52. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations
    Tan J, Degertekin B, Wong S, Husain M, Oberhelman K, Lok A. J Hepatology 2008;48:391-398.

  53. High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma
    Chan H, Tse C, Mo F, Koh J, Wong V, Wong G, Chan S, Yeo W, Sung J, Mok T. J Clin Oncol 26:177-182, 2008.

  54. HBeAg and Hepatitis B Virus DNA as Outcome Predictors During Therapy with Peginterferon Alfa-2a for HBeAg-Positive Chronic Hepatitis B
    Fried M, Piratvisuth T, Lau G, Marcellin P, Chow W, Cooksley G, Luo K, Paik S, Liaw Y, Button P, Popescu M. HEPATOLOGY 2008;47:428-434.

  55. Viral genotype and baseline load predict the reponse to adefovir treatment in lamivudine-resistant hepatitis B patients
    Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, Bonovas S, Esteban R. Journal of Hepatology 2007 ; 47:366-372.

  56. Development and Validation of a Disease-Targeted Quality of Life Instrument in Chronic Hepatitis B: The Hepatitis B Quality of Life Instrument, Version 1.0
    Spiegel B, Bolus R, Han S, Tong M, Esrailian E, Talley J, Tran T, Smith J, Karsan H, Durazo F, Bacon B, Martin P, Younossi Z, Hwa-Ong S, Kanwal F. HEPATOLOGY 2007 ; 46:113-121.

  57. Incidence of Non-Hodgkin's Lymphoma Among Individuals with Chronic Hepatitis B Virus Infection
    Yood MU, Quesenberry CP, Guo D, Caldwell C, Wells K, Shan J, Sanders L, Skovron ML, Iloeje U, Manos MM. HEPATOLOGY 2007 ; 46:107-112.

  58. Randomized Controlled Study of Tenofovir and Adefovir in Chronic Hepatitis B Virus and HIV Infection: ACTG A5127
    Peters M, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart C, Jacobson J, Johnson V, Pollard R, Rooney J, Sherman K, Swindells S, Polsky B for the ACTG Protocol A5127 Team. HEPATOLOGY 2006 ; 44:110-1116

  59. Past HBV Viral Load as a Predictor of Mortality and Morbidity from HCC and Chronic Liver Disease in a Prospective Study
    G. Chen et al. Am J Gastroenterol 2006; 101: 1797-1803

  60. A Comparison of Entecavir and Lamivudine for HBeAg-Negative Chronic Hepatitis B
    C. Lai et al. NEJM 354:10 1011-1020 Mar 06

  61. A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
    T. Chang et al. NEJM 354:10 1001-1010 Mar 06

  62. Treatment with Peg-Interferon a-2b for HbeAg-Positive Chronic Hepatitis B: HbsAg Loss Is Associated with HBV Genotype
    H. Flink et al. Am J Gastroenterol 2006 (Feb);101:297-303

  63. Notes from the NIH on Hepatitis B
    Hepatology Vol 42 number 4 October 2005 p748.

   

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2009 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource
for US healthcare providers only. Use of this Web site is governed by the CLD Foundation terms of use and privacy statement.